A new report sheds some light on biotech and pharma contract service agreements (CSAs) with CDMOs. Despite remaining shadows, it reveals less multiservice relationships and more large-molecule announcements than we might have expected.
Of 367 production plants BASF operates worldwide, six are Verbund sites. Those six produce more than 50% of all BASF volumes. A CEO of a U.S.-based CDMO thinks Verbund is the kind of thinking needed at drug development and manufacturing facilities in this country.
According to a new industry report on global bioprocessing, U.S.-based CDMOs are in a strong position. Is it so strong that capacity becomes an issue for readers relying on these service providers for new drug programs?
CDMO search and evaluation are at the core of drug development and manufacturing outsourcing. Google, the company that built an empire on returning high-quality search results, makes a case for E-A-Ting your CDMO partners.
Jonathan Freeman of Anthos Therapeutics says it’s “economic Darwinism” come visit the pharma world. Karen Fallen of Lonza admits it's “potentially highly complex.” Both believe today it's a reproducible “value-creation model.”
Fabian Stocker of SCHOTT has a soothing mathematical calculation to reduce our COVID-19 "vial shortage anxieties.” It also informs every drug developer to continue full speed ahead: There are vials for you as well.
Arena Pharmaceuticals focuses on making administration of the drug dosage form as easy as possible for the patient. “Within that simplicity,” says EVP Doug Bakan, “innovation takes place.” With help from some well-chosen CDMOs.
Today the mention of “vials” leads to questions of supplies for COVID-19 vaccines. But thoughts of vials normally pertain to your own drug develop program needs. For advice, I asked one of the biggest glass producers in the world.
We are refocused on drug development and manufacture in the U.S. But where in this big country makes the most dollars and sense for locating operations? One place drug manufacturing has traditionally flourished is Puerto Rico.
“But we forgot our people,” says an introspective biopharma executive, regarding pre-coronavirus risk assessments. Here's a look at what did and might have happened, and thoughts for the future of outsourcing.